Management of Nintedanib-Induced Diarrhea
Initial Management
- For patients with nintedanib-induced diarrhea, the European Society for Medical Oncology recommends starting loperamide at an initial dose of 4 mg followed by 2 mg every 4 hours or after every unformed stool (not to exceed 16 mg/day) 1, 2
- The American Society of Clinical Oncology suggests a conservative approach with loperamide for uncomplicated diarrhea (grade 1 or 2) without other complicating signs or symptoms 1, 3
Supportive Measures
- The National Comprehensive Cancer Network recommends implementing dietary modifications (eliminating lactose-containing products and high-osmolar dietary supplements) to help manage nintedanib-induced diarrhea 1, 3
- The European Society for Medical Oncology advises ensuring adequate oral hydration to prevent dehydration in patients with nintedanib-induced diarrhea 1, 4
- Patients should be instructed to record the number of stools and report symptoms of life-threatening sequelae, as recommended by the American Society of Clinical Oncology 3, 5
Monitoring and Follow-up
- The European Society for Medical Oncology recommends considering complicated diarrhea (fever, moderate to severe abdominal pain, or bloody diarrhea) as an indication for more aggressive management, including hospitalization with IV fluids and further evaluation 1, 3
- For complicated diarrhea, the American Society of Clinical Oncology suggests hospitalization may be necessary with IV fluids and further evaluation 2, 4
Common Pitfalls and Caveats
- The Journal of Clinical Oncology advises avoiding delaying initiation of loperamide, as early intervention may prevent progression to more severe diarrhea 5